Pfizer Inc. has completed a public debt offering totaling $6 billion across seven separate issuances. The offerings include $500 million in Floating Rate Notes due 2027, $1 billion in 3.875% Notes due 2027, $1 billion in 4.200% Notes due 2030, $1.25 billion in 4.500% Notes due 2032, $1.25 billion in 4.875% Notes due 2035, $500 million in 5.600% Notes due 2055, and $500 million in 5.700% Notes due 2065. The offering was made under the shelf registration statement on Form S-3 (Registration No. 333-277323) and the notes were issued pursuant to an indenture with The Bank of New York Mellon, as trustee. The underwriting and pricing agreements were dated November 18, 2025, and the issuance was completed on November 21, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-291406), on November 21, 2025, and is solely responsible for the information contained therein.
Comments